361 related articles for article (PubMed ID: 21394427)
21. Lack of bcr and abr promotes hypoxia-induced pulmonary hypertension in mice.
Yu M; Gong D; Lim M; Arutyunyan A; Groffen J; Heisterkamp N
PLoS One; 2012; 7(11):e49756. PubMed ID: 23152932
[TBL] [Abstract][Full Text] [Related]
22. Inflammation in Pulmonary Arterial Hypertension.
Klouda T; Yuan K
Adv Exp Med Biol; 2021; 1303():351-372. PubMed ID: 33788202
[TBL] [Abstract][Full Text] [Related]
23. Dendritic Cell Subsets and Effector Function in Idiopathic and Connective Tissue Disease-Associated Pulmonary Arterial Hypertension.
van Uden D; Boomars K; Kool M
Front Immunol; 2019; 10():11. PubMed ID: 30723471
[TBL] [Abstract][Full Text] [Related]
24. Immune and inflammatory mechanisms in pulmonary arterial hypertension.
El Chami H; Hassoun PM
Prog Cardiovasc Dis; 2012; 55(2):218-28. PubMed ID: 23009917
[TBL] [Abstract][Full Text] [Related]
25. Pulmonary hypertension: Linking inflammation and pulmonary arterial stiffening.
Liu SF; Nambiar Veetil N; Li Q; Kucherenko MM; Knosalla C; Kuebler WM
Front Immunol; 2022; 13():959209. PubMed ID: 36275740
[TBL] [Abstract][Full Text] [Related]
26. Mesenchymal stromal cell therapy reduces lung inflammation and vascular remodeling and improves hemodynamics in experimental pulmonary arterial hypertension.
de Mendonça L; Felix NS; Blanco NG; Da Silva JS; Ferreira TP; Abreu SC; Cruz FF; Rocha N; Silva PM; Martins V; Capelozzi VL; Zapata-Sudo G; Rocco PRM; Silva PL
Stem Cell Res Ther; 2017 Oct; 8(1):220. PubMed ID: 28974252
[TBL] [Abstract][Full Text] [Related]
27. Subspecificities of anticentromeric protein A antibodies identify systemic sclerosis patients at higher risk of pulmonary vascular disease.
Perosa F; Favoino E; Favia IE; Vettori S; Prete M; Corrado A; Cantatore FP; Valentini G
Medicine (Baltimore); 2016 Jun; 95(25):e3931. PubMed ID: 27336883
[TBL] [Abstract][Full Text] [Related]
28. [The etiopathogenesis of pulmonary hypertension: inflammation, vascular remodeling].
Kayikçioğlu M
Anadolu Kardiyol Derg; 2010 Aug; 10 Suppl 1():5-8. PubMed ID: 20819761
[TBL] [Abstract][Full Text] [Related]
29. B cell autophagy mediates TLR7-dependent autoimmunity and inflammation.
Weindel CG; Richey LJ; Bolland S; Mehta AJ; Kearney JF; Huber BT
Autophagy; 2015; 11(7):1010-24. PubMed ID: 26120731
[TBL] [Abstract][Full Text] [Related]
30. Platelet-derived growth factor receptor-β and epidermal growth factor receptor in pulmonary vasculature of systemic sclerosis-associated pulmonary arterial hypertension versus idiopathic pulmonary arterial hypertension and pulmonary veno-occlusive disease: a case-control study.
Overbeek MJ; Boonstra A; Voskuyl AE; Vonk MC; Vonk-Noordegraaf A; van Berkel MP; Mooi WJ; Dijkmans BA; Hondema LS; Smit EF; Grünberg K
Arthritis Res Ther; 2011 Apr; 13(2):R61. PubMed ID: 21492463
[TBL] [Abstract][Full Text] [Related]
31. A critical role for p130Cas in the progression of pulmonary hypertension in humans and rodents.
Tu L; De Man FS; Girerd B; Huertas A; Chaumais MC; Lecerf F; François C; Perros F; Dorfmüller P; Fadel E; Montani D; Eddahibi S; Humbert M; Guignabert C
Am J Respir Crit Care Med; 2012 Oct; 186(7):666-76. PubMed ID: 22798315
[TBL] [Abstract][Full Text] [Related]
32. The six-transmembrane protein Stamp2 ameliorates pulmonary vascular remodeling and pulmonary hypertension in mice.
Batool M; Berghausen EM; Zierden M; Vantler M; Schermuly RT; Baldus S; Rosenkranz S; Ten Freyhaus H
Basic Res Cardiol; 2020 Nov; 115(6):68. PubMed ID: 33188479
[TBL] [Abstract][Full Text] [Related]
33. Increased pericyte coverage mediated by endothelial-derived fibroblast growth factor-2 and interleukin-6 is a source of smooth muscle-like cells in pulmonary hypertension.
Ricard N; Tu L; Le Hiress M; Huertas A; Phan C; Thuillet R; Sattler C; Fadel E; Seferian A; Montani D; Dorfmüller P; Humbert M; Guignabert C
Circulation; 2014 Apr; 129(15):1586-97. PubMed ID: 24481949
[TBL] [Abstract][Full Text] [Related]
34. [Pulmonary arterial hypertension: a flavor of autoimmunity].
Perros F; Humbert M; Cohen-Kaminsky S
Med Sci (Paris); 2013; 29(6-7):607-16. PubMed ID: 23859515
[TBL] [Abstract][Full Text] [Related]
35. Interstitial lung disease in systemic sclerosis: pathophysiology, current and new advances in therapy.
Jain S; Shahane A; Derk CT
Inflamm Allergy Drug Targets; 2012 Aug; 11(4):266-77. PubMed ID: 22506881
[TBL] [Abstract][Full Text] [Related]
36. Leptin signalling system as a target for pulmonary arterial hypertension therapy.
Huertas A; Tu L; Thuillet R; Le Hiress M; Phan C; Ricard N; Nadaud S; Fadel E; Humbert M; Guignabert C
Eur Respir J; 2015 Apr; 45(4):1066-80. PubMed ID: 25745038
[TBL] [Abstract][Full Text] [Related]
37. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension.
Perros F; Montani D; Dorfmüller P; Durand-Gasselin I; Tcherakian C; Le Pavec J; Mazmanian M; Fadel E; Mussot S; Mercier O; Hervé P; Emilie D; Eddahibi S; Simonneau G; Souza R; Humbert M
Am J Respir Crit Care Med; 2008 Jul; 178(1):81-8. PubMed ID: 18420966
[TBL] [Abstract][Full Text] [Related]
38. Central role of T helper 17 cells in chronic hypoxia-induced pulmonary hypertension.
Maston LD; Jones DT; Giermakowska W; Howard TA; Cannon JL; Wang W; Wei Y; Xuan W; Resta TC; Gonzalez Bosc LV
Am J Physiol Lung Cell Mol Physiol; 2017 May; 312(5):L609-L624. PubMed ID: 28213473
[TBL] [Abstract][Full Text] [Related]
39. Immune and inflammatory cell involvement in the pathology of idiopathic pulmonary arterial hypertension.
Savai R; Pullamsetti SS; Kolbe J; Bieniek E; Voswinckel R; Fink L; Scheed A; Ritter C; Dahal BK; Vater A; Klussmann S; Ghofrani HA; Weissmann N; Klepetko W; Banat GA; Seeger W; Grimminger F; Schermuly RT
Am J Respir Crit Care Med; 2012 Nov; 186(9):897-908. PubMed ID: 22955318
[TBL] [Abstract][Full Text] [Related]
40. Systemic sclerosis-related pulmonary hypertension: unique characteristics and future treatment targets.
Dimitroulas T; Giannakoulas G; Karvounis H; Settas L; Kitas GD
Curr Pharm Des; 2012; 18(11):1457-64. PubMed ID: 22364130
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
